One study, performed in C57BL mice bearing ICAM-1 expressing B16 melanoma tumours, showed that the therapeutic effect of eight intratumoural injections of CVA21 is increased when combined with four intraperitoneal deliveries of antimouse-PD-1 antibodies than either therapy alone [40]. The gene discussed is ICAM1; the disease is melanoma.